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Abstract
Background: Pharmaceutical research of hyperlipidemia has been commonly pursued using traditional approaches.
However, unbiased metabonomics attempts to explore the metabolic signature of hyperlipidemia in a high-throughput
manner to understand pathophysiology of the disease process.
Methodology/Principal Findings: As a new way, we performed
1H NMR-based metabonomics to evaluate the beneficial
effects of 29,39,59-tri-acetyl-N6- (3-hydroxylaniline) adenosine (WS070117) on plasma and liver from hyperlipidemic
Syrian golden hamsters. Both plasma and liver profiles provided a clearer distinction between the control and
hyperlipidemic hamsters. Compared to control animals, hyperlipidemic hamsters showed a higher content of lipids
(triglyceride and cholesterol), lactate and alanine together with a lower content of choline-containing compounds (e.g.,
phosphocholine, phosphatidylcholine, and glycerophosphocholine) and betaine. As a result, metabonomics-based
findings such as the PCA and OPLS-DA plotting of metabolic state and analysis of potential biomarkers in plasma and
liver correlated well to the assessment of biochemical assays, Oil Red O staining and in vivo ultrasonographic imaging
suggesting that WS070117 was able to regulate lipid content and displayed more beneficial effects on plasma and liver
than simvastatin.
Conclusions/Significance: This work demonstrates the promise of applying
1H NMR metabonomics to evaluate the
beneficial effects of WS070117 which may be a good drug candidate for hyperlipidemia.
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Introduction
A novel adenosine analog, 29,39,59-tri-acetyl-N6-(3-hydroxylani-
line) adenosine (WS070117) displays anti-hyperlipidemic activity
in preliminary in vivo and in vitro experiments [1]. Serum lipids
contents, such as TC, TG, LDL-C, significantly reduced after
WS070117 treatment in high fat diet fed hamster. But these
biochemical evidences is not sufficient to figure out the difference
of metabolic profile of WS070117 when compared with other lipid
lowing agents.
Metabonomics is a global metabolite profiling approach for
biological samples, particularly, biofluids. It can be readily applied
to monitor the changes in metabolite concentration and profiles in
response to physiological and non-physiologic challenges such as drugs
or toxins [2].Applicationsof metabonomictechnologies are increasing
exponentially in biological studies such as physiological genomics and
potential lead target validation [3–5], mechanistic toxicology [6,7],
clinical pharmacology [8], and disease investigation [9–11].
Nuclear magnetic resonance spectroscopy (NMR)-based meta-
bonomics is non-discrimiating, non-invasive and little sample
preparation required which can reveal structural information for
identification of an unknown metabolite which may be a new
biomarker. Previous studies have examined the ability of NMR-
based metabonomic analysis of plasma and liver constituents to
investigate the metabolic profiling of different model animals with
hyperlipidemia related disease [12,13].
Here, we evaluated the applicability of NMR-based metabo-
nomics in assessing the effects of WS070117 on hyperlipidemic
hamsters conformed by other traditional methods as well as sought
to identify the potential biomarkers helpful to dissect the
underlying efficacies and mechanisms of WS070117. Our results
showed that WS070117 induced changes in lipids, lipid metab-
olism-related molecules, glucose, and some key amino acids in
plasma and liver in hyperlipidemic hamsters, suggesting that this
novel compound may be a good drug candidate for hyperlipide-
mia.
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Serum and hepatic biochemical parameters
The hamster, which has been established for studying diet-
induced hyperlipidemia [14,15], is considered to be a suitable
model for humans to study the hyperlipidemia induced by a high-
fat diet (HFD), since human and Syrian golden hamsters
lipoprotein and apolipoprotein profiles are similar when hamsters
are fed a high-fat diet. Herein, hamsters fed a high fat diet for 2
weeks were used to develop a dyslipidemia model (Table 1). The
liver/body weight index was markedly increased for the HFD-fed
animals at the end of the experiment. However, the indexes of the
simvastatin and WS070117 treated groups were significantly
lower. HFD also caused a marked increase in serum total
cholesterol (TC), triglyceride (TG) and low density lipoprotein
cholesterol (LDL-C) concentrations (Table 1). WS070117 treat-
ment resulted in a significant decrease in serum TC, TG, and
LDL-C concentrations. Hepatic TG concentrations were also
reduced by WS070117 (Fig. 1A). Moreover, the efficacy of
WS070117 was comparable to that of the widely used hypolip-
idemic agent simvastatin when treated with the same dose.
Ultrasonographic imaging
Ultrasonographic imaging is a non-invasive, inexpensive, and
repeatable technique used to detect fat accumulation in the liver.
Although liver ultrasonographic imaging does not provide
accurate quantification of the amount of fat present and does
not allow the severity of histological disease to be established, it is
still a non-invasive and repeatable technique to detect changes in
liver parenchyma. Normal liver has a homogeneous distribution
and the echogenicity of the entire structure is similar. Liver
parenchyma is characterized by areas with different echogenicity
[16]. Fat accumulation in liver causes increased echogenicity, and
thus the liver appears smooth and brighter. Furthermore, echo
shadows tend to be coarser in the presence of diffuse hepatic
steatosis. Differences in image texture are an important indicator
in the detection of a fatty liver.
The assessment of irregular and nodular surfaces, blunt edges,
and parenchymal abnormalities was independently blinded
reviewed and confirmed by three experienced experts according
to the unified impression for the whole imaging manifestations.
The obviously morphological changes of steatosis include
gallbladder blurring and blunt liver edge in HFD hamsters. By
ultrasonographic assay, compared to that of the model animals,
the livers from hyperlipidemic hamsters treated with simvastatin or
WS070117 had attenuated echogenicity, suggesting that treatment
reduced fat accumulation (Fig. 2).
Oil Red O staining estimation of liver fat accumulation
Oil Red O staining was performed to estimate hepatic fat
content. The hepatocytes of animals in the HFD-fed hyperlipid-
emic hamsters were compressed and separated by bulks of fat, and
the livers showed a strikingly pale yellow color, indicating an
abnormally high level of fat accumulation and deposition.
Treatment with simvastatin or WS070117 substantially repressed
these changes, and the livers from hyperlipidemic hamsters treated
with simvastatin or WS070117 had a dark red appearance similar
to that of the control animals (Fig. 1B).
Metabolite identification
With the results above, we evaluated the beneficial effects of
WS070117 by metabonomics using plasma and liver samples.
NMR-based metabonomics is a global metabolite profiling
approach for further systemic analysis. Moreover, NMR spectros-
copy can give structural information about the potential
biomarkers. Using
1H NMR spectroscopy, we investigated the
metabolic profiles of liver and plasma samples and a list of
identified metabolites are shown in Table S1.
Although there were some apparent differences between these
representative spectra based on simple visual inspection (Fig. 3),
they were not consistent across all samples. Therefore, we applied
a multivariate statistical method to analyze the spectra in a more
holistic way and to identify signals that can efficiently differentiate
the groups.
Multivariate analysis for the potential biomarkers
Metabolic changes in the plasma. After being processed by
Principal Components Analysis (PCA) and Partial Least Squares-
Discriminant Analysis (PLS-DA) in the software SIMCA-P
package, mean-centered PCA and PLS-DA score plots could be
generated to trace and compare the dynamic recovery of
metabolic events in hamsters. In the PCA and PLS-DA maps,
Table 1. Lipid-lowering effects of WS070117 (2 mg?kg
21) in serum from hyperlipideminc hamsters.
Period Parameters Control Model Simvastatin WS070117
Model
Construction
TG (mmol?L
21) 2.1160.46 3.9061.11
### 4.0560.61
### 3.5760.67
###
TC (mmol?L
21) 2.6560.16 5.5961.05
### 5.7060.72
### 5.7060.65
###
TG (mmol?L
21) 1.8560.30 9.7661.50
### 7.8660.54* 4.3060.70***
TC (mmol?L
21) 2.8660.21 7.7361.08
### 5.8760.47** 4.5160.37***
Drug
Treatment
LDL-C(mmol?L
21) 0.9260.15 3.2360.44
### 2.3360.28** 1.4460.30***
HDL-C(mmol?L
21) 1.0660.19 2.1260.47
## 1.6460.30 1.6860.27
Body weight 136614.2 182618.7
### 181623.7 192616.9
Liver/BW 0.03960.0055 0.04860.0034
### 0.04660.0018 0.04660.0056
The mean 6 SD of 5 animals are presented.
###P,0.001, compared with control;
*P,0.05,
**P,0.01,
***P,0.001, compared with model.
doi:10.1371/journal.pone.0032115.t001
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indicated a particular metabolic pattern in different state.
The PCA scores and loadings plot of the
1H Bipolar pulse pair-
longitudinal eddy current delay (BPP-LED) NMR data of plasma
samples showed an apparent higher level of low density lipoprotein/
very low density lipoprotein (LDL/VLDL) (d0.9,1.30 ppm), O-acetyl
glycoproteins (O-Ac, d2.06 ppm) and some of the lipid signals,
including CH2-CH2CO (d1.58 ppm), CH2-CH=(d2.02 ppm),
CH=CH (d5.34 ppm), and CH2-CO (d2.26 ppm), accompanied
with a lower level of high density lipoprotein (HDL) (d0.86,1.26 ppm)
andphosphatidylcholine(PtdCho)(d3.22 ppm)intheplasmasamples
of hyperlipidemic hamsters (Fig. 4A, B and Table 2).
We further analyzed the data with the Orthogonal Partial Least
Squares-Discriminant Analysis (OPLS-DA) multivariate approach,
which can separate groups in the presence of large structured noise
[17,18]. The model had an overall goodness of fit, R
2(Y), of 97%
and an overall cross-validation coefficient, Q
2(Y), of 76%. All
hyperlipidemic hamsters exhibited distinct plasma metabolic
profiles after a 10-week course of treatment with simvastatin or
WS070117. There was a remarkable decrease in lipid signals (e.g.,
LDL/VLDL, etc), suggesting that both simvastatin and
WS070117 reversed the plasma metabolic changes caused by
hyperlipidemia. Importantly, only WS070117 treatment made a
significantly statistical difference compared with simvastatin,
suggesting WS070117 had more pronounced hypolipidemic effects
(Fig. 4C, Table 2).
PCA analysis identified metabolic changes in the
1H Carr-
Purcell-Meiboom-Gill (CPMG)-NMR spectra of plasma samples
of control and hyperlipidemic hamsters; these included an increase
in the signal intensities of lactate (d1.34 ppm), alanine (d1.46 ppm)
Figure 1. WS070117 prevented liver fat accumulation in hyperlipidemic hamsters. (A): The effect of WS070117 on hepatic TG at week 10
(n=5). (B): WS070117 reduced lipid droplets in the liver of hyperlipidemic hamsters. ## P,0.001, compared with control group, **P,0.01, compared
with model group.
doi:10.1371/journal.pone.0032115.g001
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CH=CH (d5.34 ppm), accompanied by a signal reduction of
betaine (d3.26 ppm) and glycerophosphocholine (GPC) (d3.22 ppm)
in hyperlipidemic animals.
In order to select potential biomarkers worthy of preferential
study, these differential metabolites were validated using Student’s
t test. The critical p-value was set to 0.05 for significantly
differential variables in this study. The alterations of peak intensity
of the selected potential biomarkers of three groups were
summarized in Table 2. It was obvious that most of the biomarkers
in WS070117 group revealed a higher degree of recovery after 10
weeks’ therapeutic intervention.
Metabolic changes in intact liver. The liver metabolic
profiles of hyperlipidemic and control hamsters obtained by
magic-angle spinning nuclear magnetic resonance (HR-MAS)
1H-
NMR spectra displayed clear differences (Fig. 5A). PLS-DA score
plot was characterized by R
2=0.99 and Q
2=0.95. This higher
Q
2 value indicated good predictive capabilities of the model. The
predominant changes identified in the PLS-DA analysis of livers
from hyperlipidemic animals included an increase in the signal
intensities of lactate (1.34 ppm), alanine (1.46 ppm) and some lipid
signals such as -CH3, -(CH2)n-,-CH2CH=(d0.90, 0.94, 1.30, 1.34
and 2.02 ppm), accompanied by a reduction in the intensity of
betaine (d3.26 ppm) and choline-containing compounds (e.g.,
phosphocholine, GPC) (d3.22 ppm) (Fig. 5A). Treating
hyperlipidemic hamsters with simvastatin or WS070117 reverts
some of the hyperlipdemic effects on the metabolite concentrations
(Fig. 5B and C).
OPLS-DA of scores plot representing hamsters treated with
simvastatin or WS070117 shifted away from each other, indicating
that different metabolic patterns have been established due to
distinct interference, and the corresponding loadings plots
indicated that WS070117 reduced lipid accumulation in the liver
(Fig. 5D), which agrees with the Oil Red O staining results
(Fig. 1B).
The changes of peak intensity of the selected potential
biomarkers of three groups were also listed in Table 2. It revealed
that most of the biomarkers in WS070117 group revealed a higher
degree of recovery after 10 weeks’ administration.
Metabolic changes in the liver extracts. To further study
the differences between the lipid profiles of each hamster group,
the spectra of liver aqueous and lipophilic extracts were obtained
(Fig. 6). Metabolic profiles of the hydrophilic extracts of
hyperlipidemic hamsters and control animals were mostly the
same, as assessed by the
1H CPMG-NMR spectra. Signals
attributed to cholesterol (in free and esterified form) triglycerides,
phospholipids and fatty acid residues comprised the total lipid
extract NMR fingerprint (Fig. 6B). The main differences between
hyperlipidemic and control hamsters were related to the structural
features of the fatty acids and cholesterol.
The HR-MAS
1H-NMR spectrum revealed information on
metabolites found in both aqueous and lipophilic extracts; detailed
analysis suggested a pronounced difference in the content of
hepatic lipids and choline-containing compounds between
WS070117 treated and untreated hyperlipidemic golden hamsters.
Not surprisingly, the metabolic differences between simvastantin
and WS070117 treated hyperlipidemic hamsters were consistent
with the results observed in intact livers by HR-MAS NMR
(Fig. 5).
Discussion
Based on the results of conventional pharmacological methods,
it was found that the hyperlipidemic hamster model induced by
HFD had been successfully established. Treatment with
WS070117 made a significant reverse that resulted in decreases
serum TC, TG, LDL-C and hepatic TC and TG. The liver Oil
Red O staining and ultrasonographic image data show that
Figure 2. Various echogenicity in hamster liver tissue demon-
strates that WS070117 prevents fat accumulation in the liver.
(A) Images of pericholecystic space; (B) Images of liver edge.
doi:10.1371/journal.pone.0032115.g002
WS070117 and Hyperlipidemic Hamsters
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hyperlipidemic hamsters. These evidences were concluded that
WS070117 had a lipid-regulating effect on both plasma and liver.
Simvastatin perform the similar lipid lowing effect in this model.
However, the above results were difficult to figure out the
advantage of WS070117 compared with simvastatin at the same
dosage administration.
Using NMR-based metabonomics it is possible to ‘bridge the
gap’ between biofluid analysis and histopathology and to gain real
insight into the mechanisms of drug efficacy at a molecular level.
Thus, we applied NMR-based metabonomics to analyze in a
holistic way for marker metabolites and to identify signals that can
efficiently differentiate the groups, which can hardly be found by
the conventional pharmacological methods.
In the present study, we explored the pattern recognition
analysis such as PCA and OPLS-DA model to identify the
metabolites that were characteristic of the group with hyperlipi-
demia and drug intervention. It was observed that higher
concentrations of lipids (triglycerides and cholesterol), lactate,
alanine together with lower concentrations of choline-containing
compounds (e.g. phosphocholine, PtdCho, GPC), betaine in
plasma and liver samples from hyperlipidemic hamsters compared
to controls. However, the levels of these metabolites reversed when
hyperlipidemic hamsters were treated with Simvastatin or
WS070117. The intact tissues ex vivo assay by high resolution
magic-angle spinning (HR MAS) NMR spectroscopy also showed
that the pronounced differences in hepatic lipid content and
choline-containing compounds between hyperlipidemic golden
hamsters treated and untreated with WS070117. For the detection
of lipid metabolites, NMR-based metabonomics presented consis-
tent results with the biochemistry method. Moreover, this
technology can find many other metabolites that significant
contributed to distinguish among the groups.
More importantly, the results of NMR-based metabonomics
gave us highlight on WS070117 that it had different hypolipidemic
feature compared to Simvastatin. Here, Simvastatin mainly show a
lipid-lowering effect and hardly made changes in low molecular
weight metabolites that perform a vital role in lipid metabolism.
Further study revealed that the main differential endogenous
metabolites identified in liver and plasma of hyperlipidemic
Figure 3. Typical 500 MHz
1H-NMR spectra of hamster plasma and liver samples. (A):
1H-NMR BPP-LED spectra of plasma samples. (B):
1H-
NMR CPMG spectra of plasma samples. (C): HR-MAS
1H-NMR standard spectra of liver tissues. Signal assignment: VLDL, very low-density lipoprotein;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; PtdCho, Phosphatidylcholine; Ile, Isoleucine; Leu, Leucine; 3-HB, 3-D-Hydroxybutyrate;
Val, Valine; Eth, (residual) Ethanol; Lac, Lactate; Ala, Alanine; Lys, Lysine; Ace, Acetate; N-Ac, N-Acetyl glycoproteins; O-Ac, O-Acetyl glycoproteins; Met,
Methionine; Pyr, Pyruvate; Gln, Glutamine; Cho, Choline; GPC, Glycerophos- phorylcholine; Glc, Glucose; TMAO, Trimethylamine-N-oxide.
doi:10.1371/journal.pone.0032115.g003
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metabolism-related molecules, and some key amino acids. These
observations summarized below increased our understanding of
the metabolism pathways involved in the lipid lowing effect of
WS070117 on HFD induced hyperlipidmia.
The changes of macromolecules in plasma caused by
WS070117 contained apparent lower levels of LDL/VLDL, O-
Ac and some of the lipid signals including CH2-CH2, CH=CH,
C2 and C3 protons of fatty acids, accompanied with higher levels
of HDL and PtdCho than those in hyperlipidemic hamsters. An
Figure 4. PR analysis of
1H-NMR BPP-LED spectra of hamster plasma. (A): PCA scores plot of
1H-NMR BPP-LED spectra of plasma samples
from normal and hyperlipidemic hamsters (R
2X=0.998, Q
2=0.808). (B): Corresponding loadings plot indicating those NMR spectral regions
responsible for the separation. (C): Scores plot of OPLS-DA analysis of the spectra of hamster plasma (R
2X=0.994, R
2Y=0.518, Q
2=0.347).N, Control
hamsters; &, Hyperlipidemic hamsters; m, Hyperlipidemic hamsters treated with simvastatin (2 mg?kg
21); *, Hyperlipidemic hamsters treated with
WS070117 (2 mg?kg
21).
doi:10.1371/journal.pone.0032115.g004
Table 2. Relative integrals from some selected metabolites contributing to the classification of hamsters in four groups.
Biological
matrices Metabolites Control Model WS070117 Simvastatin p- value
Plasma HDL
& 0.04660.0022 0.03060.0024 0.03760.0057 0.03460.0054 4.7610
26a, 0.036
b, 0.17
c
LDL/VLDL
& 0.03560.0027 0.05960.0037 0.05160.0050 0.05860.0060 2.4610
26a, 0.019
b, 0.92
c
Lactate
& 0.03860.0042 0.1060.0034 0.07560.0063 0.09060.0089 3.9610
29a,2 . 5 610
25b, 0.013
c
Alanine
& 0.001360.00044 0.003460.0006 0.002260.0004 0.003160.0005 2.0610
24a, 0.0063
b, 0.34
c
O-Acetyl glycoproteins
& 0.01660.0010 0.02060.0007 0.01760.0012 0.01860.0011 1.3610
24a, 0.0039
b, 0.040
c
Betaine
& 0.004960.0009 0.002760.0003 0.004860.0013 0.003860.0011 6.2610
24a, 0.0084
b, 0.083
c
PtdCho
& 0.02360.0020 0.01060.0009 0.01860.0039 0.01460.0040 1.0610
26a, 0.0019
b, 0.055
c
GPC
& 0.03160.0042 0.01860.0036 0.02860.0044 0.02260.0089 9.4610
24a, 0.0046
b, 0.39
c
Liver Lipids-CH3
& 0.01860.0018 0.02660.0040 0.02460.0033 0.02660.0039 0.0032
a, 0.49
b, 0.96
c
Lipids-(CH2)n
& 0.03160.0048 0.06860.0131 0.05560.0161 0.06360.0131 3.3610
24a, 0.32
b, 0.73
c
Lipids-CH2CH=
& 0.009260.00082 0.01260.0014 0.01160.0013 0.01260.0013 0.0048
a, 0.35
b, 0.77
c
Lactate
& 0.03060.0022 0.07360.0173 0.05660.0178 0.06360.0065 6.2610
24a, 0.19
b, 0.35
c
Alanine
& 0.01360.0015 0.01760.0020 0.01460.0006 0.01760.0015 0.013
a,7 . 1 610
24b, 0.47
c
Betaine
& 0.02260.0032 0.01660.0022 0.02060.0013 0.01860.0012 0.010
a, 0.0052
b, 0.080
c
GPC
& 0.01160.0021 0.007960.0014 0.009260.0012 0.008360.0005 0.015
a, 0.086
b, 0.38
c
&, normalized to the total of all the resonance integral regions over the range of 0.5–6.0 ppm excluding the resonance from residual water (4.7–5.1 ppm);
a, Model group compared with Control;
b, WS070117 (2 mg?kg
21) treated group compared with Model;
c, Simvastatin (2 mg?kg
21) treated group compared with Model.
doi:10.1371/journal.pone.0032115.t002
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with the higher level of HDL since PtdCho is the most
predominant lipid in the HDL fraction [19–21]. The total lipid
concentration in the plasma of hyperlipidemic hamsters with
administration of WS070117 was lower than that in untreated
hyperlipidemic ones, as indicated by the loadings of resonances at
d2.26 ppm and d1.58 ppm, contributed from the C2 and C3
protons of fatty acids. The micro-molecules in plasma of
hyperlipidemic hamsters treated by WS070117 changed, including
a reduction in the signals of lactate and alanine accompanied with
an increase in betaine and GPC. These micro-molecular is
involved in various pathway of energy metabolism. It was found
lower lactate and total lipid levels in hyperlipidemic hamsters
administrated with WS070117, suggesting that the rate of
glycolysis was reduced and the energy consumption was switched
to lipid oxidation [22]. Much of the alanine released from skeletal
muscle comes from transamination of pyruvate formed during
glycolysis and it can be transported in the blood to provide a liver
gluconeogenesis substrate through the glucose-alanine cycle [23].
Therefore, the reduction in alanine caused by WS070117 may
indicate that muscle proteins degration and liver gluconeogenesis
was inhibited.
In liver tissues from hyperlipidemic hamsters, WS070117
treatement decreased levels of lipids (e.g.CH3, (CH2)n,C H 2-
CH=, CH2CO etc.), lactate, alanine and increased levels of
choline-containing compounds (e.g. phosphorcholine, GPC), and
betaine. Triglycerides are normally exported from the liver in the
form of VLDL particles, which also contain relatively high
concentrations of free cholesterol. Since VLDL synthesis requires
the availability of phospholipids, particularly PtdCho, an insuffi-
ciency of PtdCho or its precursors can lead to decreased secretion
of triglycerides from the liver and hence fatty liver. WS070117
increased levels of phospholipids (i.e. PtdCho) in hyperlipidemic
hamsters, so it can promote triglycerides export from the liver to
prevent fat accumulation. WS070117 was also found to increase
hepatic GPC, which may be an indicator of liver ‘‘functionality’’
[13]. It was reported that betaine decreased the contents of hepatic
cholesterol and total lipids in rats consuming a high-cholesterol
diet [24].
In summary, these findings showed that NMR-based metabo-
lomics did give a better picture of the multiparametric response to
hyperlipidemia and pharmacological intervention, which con-
firmed by the significant deviation of biomarkers in the model
group compared with normal controls and their recovery in
treatment groups. Most interesting, the metabonomic study
provided a visualized pattern and relative quantitative estimation
to evaluate the effect of WS070117. In previous studies,
WS070117 proved to be an activation agent of AMPK while
simvastatin is a classical HMG-CoA reductase inhibitor. The
different targets may result in the metabonomic diversity of
WS070117 and simvastatin. Furthermore, future investigations of
the relevance between metabolic profiles and target activation are
needed to generate a more complete understanding of the
hypolipidemic effects of WS070117.
Materials and Methods
Ethics statement
All protocols in this study were approved by the Medical Ethic
Committee of Peking Union Medical College and were in
accordance with National Institutes of Health regulations for the
care and use of animals in research.
Diets
The normal standard chow diet was purchased from Beijing
HFK Bioscience Co. Ltd. The HFD was prepared by mixing
Figure 5. PR analysis of HR-MAS
1H-NMR standard spectra of hamster liver tissues. (A): PCA analysis of the spectra of liver tissues from
normal and hyperlipidemic hamsters (R
2X=0.997, Q
2=0. 945). (B), (C) and (D): Scores plot of pair-wised OPLS-DA analysis of the spectra of liver tissues
from untreated and treated hyperlipidemic hamsters ((B) R
2X=0.98, R
2Y=0.97, Q
2=0.762; (C) R
2X=0.979, R
2Y=0.942, Q
2=0.723; (D) R
2X=0.988,
R
2Y=0.968, Q
2=0.838).N, Control hamsters; &, Hyperlipidemic hamsters; m, Hyperlipidemic hamsters treated with simvastatin (2 mg?kg
21); *,
Hyperlipidemic hamsters treated with WS070117 (2 mg?kg
21).
doi:10.1371/journal.pone.0032115.g005
WS070117 and Hyperlipidemic Hamsters
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cholesterol (2 g/kg HFD).
Care and maintenance of animals
Twelve-month-old Syrian golden hamsters were purchased
from Vital River Laboratory Animal Technology Co. Ltd. Twenty
adult male Syrian golden hamsters (90–110 g) were acclimatized
for 7 days in cages prior to model construction. They were given
ad libitum access to food and water and maintained on a 12 h
light/dark cycle (2162uC with a relative humidity of 45610%).
Hyperlipidemic model construction
The animals were then randomly allocated into two groups,
control (n=5) and hyperlipidemic (n=15). The hamsters that
served as control group were fed ad libitum access to the standard
chow, whereas the hyperlipidemic hamsters were fed a high-fat
diet (Institute of Laboratory Animal Sciences, Beijing) 12g/
animal/day quantitative feed to prevent animal store too much
food in their cheek pouch for 2 weeks to establish the
hyperlipidemic model.
Drug administration
The hyperlipidemic hamsters were divided into three groups
based on triglyceride and cholesterol levels in serum and body
weight; these were the model group and the simvastatin- or
WS070117-treated groups (2 mg?kg
21) (n=5). The control and
model hamsters were orally administered 2.5% carboxymethyl
cellulose sodium (CMC-Na). All drugs were given once daily by
oral gavage for 10 weeks. The animals in control and model group
received the same volume of CMC-Na as that of the drug-treated
group. The high fat diet was also administered the same quantity
as model construction during the drug intervention.
Ultrasonographic imaging
On the 10th week of drug administration and following an overnight
fasting, the animals were anesthetized by inhalation of 1.5%–2%
isoflurane gas. After removing hair from the abdomen and anchoring
the limbs to a constant temperature circuit platform in a supine
position, the animals were examined for their livers using an ultra
imager (VisualSonics Vevo 770H High-Resolution Imaging System)
equipped with a real-time micro-visualization scan-head probe.
Figure 6. High resolution 500 MHz single pulse
1H-NMR spectra of liver tissue extracts from control hamsters. (A):
1H-NMR spectrum of
liver tissue aqueous extracts from control hamsters. (B):
1H-NMR spectrum of liver tissue chloroform/methanol extracts from control hamsters. Signal
assignment: 1, Bile acid C18 methyls; 2, Isoleucine; 3, Leucine; 4, Valine; 5, b-Hydroxybutyrate; 6, Lactate; 7, Alanine; 8, Lysine; 9, Acetate; 10,
Glutamate; 11, Glutamine; 12, Glutathione; 13, Succinate; 14, Aspartate; 15, Tyrosine; 16, Choline; 17, Phosphocholine; 18, Glycerophosphorcholine;
19,Trimethylamine-N-oxide; 20, Betaine; 21, N-methyl nicotinamide; 22, b-Glucose; 23, a-Glucose; 24, Glycogen; 25, UDP-Glucose; 26, NAD
+; 27,
NADP
+; 28, Inosine&adenosine; 29, AMP; 30, Fumarate; 31, Histidine; 32, Nicotinurate; 33, Adenine; 34, Adenosine; 35, Cholesterol (C18H3); 36, Fatty
acid residues (v-CH3); 37, Cholesterol (C26H3,C 27H3,C 21H3); 38, Fatty acid residues (v-CH3 of total omega-3 fatty acid); 39, Cholesterol (C19H3); 40,
Fatty acid residues ((CH2)n); 41, Fatty acid residues (COCH2-CH2); 42, Fatty acid residues (-CH2 of ARA+EPA); 43, Fatty acid residues (CH2-CH=); 44,
Fatty acid residues(-CO-CH2); 45, Fatty acid residues (a and b CH2 of DHA); 46, Fatty acid residues (-CH=CH-CH2-CH=CH-of linoleic acid); 47, Fatty
acid residues (CH=CH-CH2-CH=CH)n,n .1; 48, CH2-NH2 of PE; 49, N
+(CH3)3 (PC and SM); 50, Cholesterol (C3H); 51, Triglycerides (C1H and C3Ho f
glycerol); 52, Triglycerides (C1H and C3H of glycerol); 53, Triglycerides (C2H of glycerol); 54, Fatty acid residues (CH=CH); 55, Cholesterol (C6H). ARA,
Arachidonic acid; EPA, Eicosapentaenoic acid; DHA, Doco- sahexaenoic acid; PE, Phosphatidylethanolamine; PC, Phosphatidylcholine; SM, Sphingo-
myelin.
doi:10.1371/journal.pone.0032115.g006
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Hamsters were anesthetized with an intra-peritoneal injection of
3% sodium pentobarbital (2 ml per kg). An abdominal incision
was made to expose the liver and inferior vena cava. Blood (3–
4 ml) was withdrawn from the abdominal aorta and collected in
tubes with or without heparin for collecting plasma and serum,
respectively. The contents of serum TG, TC, LDL-C, and HDL-C
were measured using commercial enzymatic assays (BioSino Bio-
technology and Science Inc). Each sample was assayed in
duplicate.
Measurement of the hepatic TC and TG contents
After blood collection, the liver was excised and weighed. The
right lateral liver was frozen for biochemical analysis. One
hundred milligrams of frozen liver tissue was thawed and
homogenized in 2 ml of chloroform-methanol (2:1). After
homogenization, lipids were extracted by rocking the samples for
1 h at room temperature followed by centrifugation at 5,000 g for
10 min. One milliliter of lipid extract was dried under a nitrogen
stream and re-dissolved in 1 ml of isopropanol. TC and TG
contents were measured using commercial kits.
Oil Red O staining
Sections of liver tissue were fixed in 4% paraformaldehyde and
dehydrated in a 30% sucrose solution at room temperature.
Tissues were then immersed in Optimal Cutting Temperature
(OCT) solution on dry ice. Three hamsters were randomly picked
from each group and 3 different tissue sections from each liver
were processed and stained using routine laboratory procedures.
Sample collection for NMR analysis
Plasma and intact liver collection. Blood samples in
heparinized tubes were centrifuged at 12,000 g for 15 min and
the supernatant was collected. The left lateral lobe was taken from
the total liver and immediately snap-frozen in liquid nitrogen.
Both plasma and liver samples were stored at 193 K for
1H-NMR
analysis.
Liver extraction procedure. Samples of intact frozen livers
(,0.5 g) were weighed and transferred into glass vials. The
samples were homogenized with 2 ml of methanol and 425 ml
water. One ml chloroform was added to the sample and vortexed.
Then additional 1 ml chloroform and 1 ml water were added and
the samples were vortexed again. The samples were kept on ice for
15 min and centrifuged at 1,000 g for 15 min at 277 K. The
solution was separated into an upper methanol/water phase (with
aqueous metabolites) and a lower chloroform phase (with
lipophilic compounds), separated by protein and cellular debris.
The upper and lower layers were transferred into separate glass
vials. The solvent was removed under a stream of nitrogen.
Aqueous and lipophilic extracts were stored at 193 K until analysis
[25].
1H-NMR spectroscopy
All NMR experiments were performed on a Bruker
AVANCE III-500 spectrometer (Bruker Biospin, Germany)
operating at a
1H frequency of 500.13 MHz. Plasma spectra
were recorded at 298 K by a triple resonance inverse TXI [
1H,
13C,
15N]-xyz triple axis gradient probe, and data for intact liver
samples were acquired at 277 K using HR MAS probe at a
spinning rate of 4 kHz. A 90upulse length was adjusted for each
sample. 128 transients were collected into 32 k data points for
each spectrum with a spectral width of 20 ppm and a recycle
delay of 4.0 s.
Three kinds of
1H NMR spectra were acquired: a standard one-
dimensional pulse sequence using the first increment of the
NOESY pulse sequence to achieve water pre-saturation, a Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence [25] to enhance
the contribution of low molecular weight metabolites, and a
diffusion-edited experiment using a bipolar pulse pair-longitudinal
eddy current delay (BPP-LED) pulse sequence [25–27] to observe
the lipid contents of lipoproteins in plasma. For the standard one-
dimensional experiment, the mixing time (tm) was 100 ms. For the
CPMG experiment, a spin-spin relaxation delay of 320 ms was
used for each sample, and water signal irradiation was applied
during the recycle delay. For the BPP-LED experiment, a sine
shaped gradient with strength of 32 G/cm and duration of 2.5 ms
was followed by a delay of 400 ms to allow for the decay of eddy
currents. A diffusion delay of 120 ms and a delay Te of 5 ms were
used. A line-broadening factor of 0.3–1 Hz was applied to FIDs
before Fourier transformation.
1H-NMR spectroscopy of plasma
Thirty ml of plasma was added to 60 ml of 0.9% saline
(D2O:H2O=1:9) containing 0.1% sodium 3-trimethylsilyl-propi-
onate-2,2,3,3,-d4 (TSP) (an internal standard, chemical shift d
0.0 ppm) in Eppendorf tubes. Samples were centrifuged at
12,0006g for 5 min at 298 K, and 60 ml of sample was transferred
into 1.7-mm NMR tubes. 1D NOESY, CPMG and BPP-LED
spectra were recorded.
HR-MAS
1H-NMR spectroscopy of intact liver
All material in contact with the tissue was cooled to at least
277 K to reduce degradation during the sample preparation
process. Frozen samples taken from a 193 K freezer were placed
in a cryo-vial in liquid N2 until insertion into a 4-mm (o.d.) ZrO2
rotor. The pre-cooled rotor was filled with cooled D2O with 0.1%
TSP after sample insertion. Spherical inserts were used to limit the
rotor inner volume to 12 ml.
1H-NMR spectra of liver tissues were
recorded using a standard 1D-NOESY and the CPMG pulse
sequence.
1H-NMR spectroscopy of liver extracts
The aqueous extracts were reconstituted in 80 mlD 2O
containing 0.1% TSP. After centrifugation (1,000 g, 5 min),
60 ml of the supernatant were transferred to 1.7-mm NMR tubes.
The
1H-NMR spectra of aqueous extracts were recorded using a
water suppression pulse sequence, such as 1D NOESY-presat. For
recording the
1H-NMR spectra of the lipophilic extracts, pre-
saturation of the water resonance is not required, and thus a
simple 90u pulse-acquire sequence was used.
Relative quantification and statistical analysis
Relative intensities of some specific metabolites were deter-
mined using a selective signal of each metabolite from normalized
spectra and results were represented as mean 6 SD.
The other biochemical data were also expressed as the mean 6
SD of five hamsters per group. Statistical analysis was performed
using one-way ANOVA. A calculated P-value of less than 0.05 was
considered statistically significant.
Metabolite identification
Both visual inspection of the raw spectral data and statistical
analysis were applied to identify discriminating peaks. Plasma and
liver metabolites were identified with reference to published
literature [28–29] and the Chenomx NMR Suite (Chenomx,
Calgary, Canada).
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(PR) analysis
The acquired NMR spectra were referenced to the chemical
shift of TSP. Following phase and baseline correction, the
1H-
NMR spectra were automatically reduced to ASCII files using
AMIX software (Analysis of MIXtures software v. 3.0, Bruker
Biospin). Each spectrum over the range of 0.5–6.0 ppm was data
reduced and normalized to the total of all the resonance integral
regions. The regions containing the resonance from residual water
(4.7–5.1 ppm) were excluded. Residual ethanol resonances (1.17–
1.23 ppm and 3.62–3.67 ppm) were also removed. Each reduced
‘‘buckets’ has an equal width of 0.04 ppm and each integral region
was thus effectively standardized to a ratio of the total metabolites
detected in the sample. The ASCII files were imported into
Microsoft Excel for labeling and then imported into SIMCA-P12.0
(Umetrics, Umea ˚, Sweden) for the PR analysis. Prior to analyses,
the values of all variables were centered and scaled.
Principal components analysis (PCA) was used to reduce the
dimensionality of the data sets and to produce an overview of the
data set. PCA was also applied to identify outliers and detect data
grouping or separation trends. The corresponding loadings plots
were used to identify which spectral variables contribute to the
positioning of the samples on the scores plot and hence the
variables that influence any observed separation in the dataset.
Data were visualized with the PC scores plots, where each point
represents an individual spectrum of a sample, and loadings plots,
where each point represents a single NMR spectral region or
chemical shifts. From the score and loading plots, classification of
samples and the biochemical components responsible for the
classification, respectively, can be shown.
The supervised pattern recognition (PLS-DA) was more focused
on the actual class discriminating variation in the data compared to
theunsupervisedapproach(PCA).PLS-DAisafrequentlyusedPLS-
based classification method in which the response variables are
categorical (dummy variables describing the categories) and describe
the class membership of the statistical units.PLS-DA aims to find the
best possible discriminant function (model) separating classes of
observations based on their X variables. When group separation was
notsatisfiedbased onPLS-DA,thedatawerefurtherprocessedusing
orthogonal signal correction (OSC) which removes linear combina-
tions of variables X orthogonal to the Y vector of the dependent
variables, and thus eliminates inter-subject variability and generates
maximum class separations [30]. The PLS-DA model was validated
by permutation method with describing R
2Ya n dQ
2Y values. The
parameter Q
2 was used to provide an estimation of the predictive
capability of the PLS-DA models with Q
2.0.5 considered ‘good’
and Q
2.0.9 ‘excellent’. The parameter R
2 describes the explained
variation and how well the data can be mathematically reproduced
by the training model. Commonly, R
2Y provides an estimate of how
well the model fits the Y data, whereas Q
2Y is an estimate of how
well the model predicts the Y. The fact that both Q
2Ya n dR
2Ya r e
close to 1 indicates an excellent model, whereas the poor ratio of
them is likely to be the onset of model overfitting [31].
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